[go: up one dir, main page]

MX2011012491A - Administracion continua de cilengitida en tratamientos contra el cancer. - Google Patents

Administracion continua de cilengitida en tratamientos contra el cancer.

Info

Publication number
MX2011012491A
MX2011012491A MX2011012491A MX2011012491A MX2011012491A MX 2011012491 A MX2011012491 A MX 2011012491A MX 2011012491 A MX2011012491 A MX 2011012491A MX 2011012491 A MX2011012491 A MX 2011012491A MX 2011012491 A MX2011012491 A MX 2011012491A
Authority
MX
Mexico
Prior art keywords
continuous administration
cilengitide
cancer treatments
therapy
ligands
Prior art date
Application number
MX2011012491A
Other languages
English (en)
Inventor
Martin Andreas Picard
Ullrich Bethe
Matthias Dotzauer
Elizabeth Cohen-Jonathan Moyal
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43223150&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2011012491(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2011012491A publication Critical patent/MX2011012491A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invención se relaciona con una terapia de combinación para el tratamiento de tumores y metástasis tumorales que comprende la administración continua de ligandos de integrina, preferiblemente antagonistas de integrina junto con un agente coterapéutico o formas de terapia que tengan eficacia sinergística cuando se administren de manera consecutiva con los ligandos, tales como agentes quimioterapéuticos y/o radioterapia.
MX2011012491A 2009-05-25 2010-05-25 Administracion continua de cilengitida en tratamientos contra el cancer. MX2011012491A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09006941 2009-05-25
PCT/EP2010/003162 WO2010136168A2 (en) 2009-05-25 2010-05-25 Continuous administration of integrin ligands for treating cancer

Publications (1)

Publication Number Publication Date
MX2011012491A true MX2011012491A (es) 2011-12-14

Family

ID=43223150

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011012491A MX2011012491A (es) 2009-05-25 2010-05-25 Administracion continua de cilengitida en tratamientos contra el cancer.

Country Status (16)

Country Link
US (1) US20120130146A1 (es)
EP (1) EP2445534A2 (es)
JP (1) JP2012528079A (es)
KR (1) KR20120104491A (es)
CN (1) CN102448497A (es)
AU (1) AU2010252280A1 (es)
BR (1) BRPI1011206A2 (es)
CA (1) CA2763275A1 (es)
CL (1) CL2011002962A1 (es)
EA (1) EA201101651A1 (es)
EC (1) ECSP11011552A (es)
IL (1) IL216537A0 (es)
MX (1) MX2011012491A (es)
NZ (1) NZ597339A (es)
SG (1) SG176103A1 (es)
WO (1) WO2010136168A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2593122A1 (en) * 2010-07-16 2013-05-22 Merck Patent GmbH Peptide for use in the treatment of breast cancer and/or bone metastases
JP6049712B2 (ja) 2011-07-08 2016-12-21 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒルＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｎｏｒｔｈ Ｃａｒｏｌｉｎａ Ａｔ Ｃｈａｐｅｌ Ｈｉｌｌ 抗癌治療及び画像化並びに骨障害治療のための金属ビスホスホネートナノ粒子
EP2780363B1 (en) 2011-11-17 2019-07-03 Glia SP Z.O.O. Compositions and methods for treating glioma
KR101470700B1 (ko) * 2011-11-25 2014-12-12 서울대학교산학협력단 표적 항암제의 내성 극복 방법
JP6458007B2 (ja) * 2014-04-04 2019-01-23 大鵬薬品工業株式会社 抗腫瘍性白金錯体を含有する抗腫瘍剤及び抗腫瘍効果増強剤
US10806694B2 (en) 2014-10-14 2020-10-20 The University Of Chicago Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof
CN107001031B (zh) * 2014-10-14 2019-11-15 芝加哥大学 一种金属有机框架、药物制剂及其在制备药物中的用途
JP7090034B2 (ja) 2016-05-20 2022-06-23 ザ ユニバーシティ オブ シカゴ 化学療法、標的療法、光線力学療法、免疫療法及びそれらの任意の組み合わせのためのナノ粒子
JP7232204B2 (ja) * 2017-06-29 2023-03-02 インサイテック・リミテッド マイクロバブル強化超音波処置における超音波周波数およびマイクロバブルサイズの最適化
US11826426B2 (en) 2017-08-02 2023-11-28 The University Of Chicago Nanoscale metal-organic layers and metal-organic nanoplates for x-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US5260291A (en) 1981-08-24 1993-11-09 Cancer Research Campaign Technology Limited Tetrazine derivatives
US4578079A (en) 1982-08-04 1986-03-25 La Jolla Cancer Research Foundation Tetrapeptide
US4661111A (en) 1982-08-04 1987-04-28 La Jolla Cancer Research Foundation Polypeptide
US4517686A (en) 1982-08-04 1985-05-21 La Jolla Cancer Research Foundation Polypeptide
US4589881A (en) 1982-08-04 1986-05-20 La Jolla Cancer Research Foundation Polypeptide
US4792525A (en) 1982-08-04 1988-12-20 La Jolla Cancer Research Foundation Tetrapeptide
US4614517A (en) 1982-08-04 1986-09-30 La Jolla Cancer Research Foundation Tetrapeptide
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
AU6290090A (en) 1989-08-29 1991-04-08 University Of Southampton Bi-or trispecific (fab)3 or (fab)4 conjugates
CA2093022C (en) 1990-10-05 2005-02-22 Michael W. Fanger Targeted immunostimulation with bispecific reagents
CA2097060A1 (en) 1990-12-04 1992-06-05 Peter J. Curtis Bifunctional antibodies and method of preparing same
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
ATE503496T1 (de) 1992-02-06 2011-04-15 Novartis Vaccines & Diagnostic Biosynthetisches bindeprotein für tumormarker
US5407804A (en) 1992-05-22 1995-04-18 Applied Genetics Inc. Assays for O6 -methylguanine-DNA methyltransferase
GB9224888D0 (en) 1992-11-27 1993-01-13 Univ Singapore Monoclonal antibody
DK0672142T3 (da) 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
US5753230A (en) 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
DE69528829T2 (de) 1994-05-27 2003-08-07 Merck & Co., Inc. Präparate zur hemmung der durch osteoklasten vermittelten knochenresorption
NZ290008A (en) 1994-06-29 1998-08-26 Smithkline Beecham Corp Vitronectin receptor antagonists, comprising a fibrinogen antagonist analogue linked to a heterocycle
ZA955391B (en) 1994-06-29 1996-02-09 Smithkline Beecham Corp Vitronectin receptor antagonists
IT1271688B (it) 1994-08-04 1997-06-04 Menarini Ricerche Sud Spa Molecole ibride per il trattamento antitumorale loro preparazione e loro uso in composizioni farmaceutiche
EP0777657A1 (en) 1994-08-22 1997-06-11 Smithkline Beecham Corporation Bicyclic compounds
WO1996026190A1 (en) 1995-02-22 1996-08-29 Smithkline Beecham Corporation Integrin receptor antagonists
US5780426A (en) 1995-06-07 1998-07-14 Ixsys, Incorporated Fivemer cyclic peptide inhibitors of diseases involving αv β3
WO1997001540A1 (en) 1995-06-29 1997-01-16 Smithkline Beecham Corporation Integrin receptor antagonists
DE19534177A1 (de) 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
BR9612378A (pt) 1995-12-29 1999-07-13 Smithkline Beecham Corp Antagonistas receptores de vitronectina
CZ203898A3 (cs) 1995-12-29 1999-03-17 Smithkline Beecham Corporation Antagonista vitronektinového receptoru, farmaceutický přípravek s jeho obsahem, způsob a použití
TR199801253T2 (xx) 1995-12-29 1998-12-21 Smithkline Beecham Corporation Vitronektin resept�r� antagonistleri.
CA2249471A1 (fr) 1996-03-20 1997-09-25 Hoechst Marion Roussel Composes tricycliques ayant une activite vis-a-vis des integrines notamment vis-a-vis de l'integrine alphavbeta3, leur procede de preparation et les intermediaires de ce procede, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant
DE69716900T2 (de) 1996-04-10 2003-07-03 Merck & Co., Inc. Alpha v Beta 3 ANTAGONISTEN
US5925655A (en) 1996-04-10 1999-07-20 Merck & Co., Inc. αv β3 antagonists
WO1997041844A1 (en) 1996-05-09 1997-11-13 Alcon Laboratories, Inc. Combinations of angiostatic compounds
ATE470450T1 (de) 1996-05-31 2010-06-15 Scripps Research Inst Zusammenstellungen zur verwendung als alpha-v- beta3 vermittelter angiogenesis hemmers
US5786146A (en) 1996-06-03 1998-07-28 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
US6017704A (en) 1996-06-03 2000-01-25 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
WO1998008840A1 (en) 1996-08-29 1998-03-05 Merck & Co., Inc. Integrin antagonists
US5981546A (en) 1996-08-29 1999-11-09 Merck & Co., Inc. Integrin antagonists
JP2001501951A (ja) 1996-10-07 2001-02-13 スミスクライン・ビーチャム・コーポレイション 骨形成刺激方法
WO1998018461A1 (en) 1996-10-30 1998-05-07 Merck & Co., Inc. Integrin antagonists
ES2194223T3 (es) 1996-10-30 2003-11-16 Merck & Co Inc Antagonistas de la integrina.
US5919792A (en) 1996-10-30 1999-07-06 Merck & Co., Inc. Integrin antagonists
EP0963370B1 (en) 1996-12-09 2003-03-19 Eli Lilly And Company Integrin antagonists
DE19653645A1 (de) 1996-12-20 1998-06-25 Hoechst Ag Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung
DE19653646A1 (de) 1996-12-20 1998-06-25 Hoechst Ag Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung
DE19653647A1 (de) 1996-12-20 1998-06-25 Hoechst Ag Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung
CO4920232A1 (es) 1997-01-08 2000-05-29 Smithkline Beecham Corp Acidos aceticos dibenzo [a,d] cicloheptano con actividad antagonista del receptor de vitronectin
WO1998031359A1 (en) 1997-01-17 1998-07-23 Merck & Co., Inc. Integrin antagonists
IL132560A0 (en) 1997-05-02 2001-03-19 Genentech Inc A method for making multispecific antibodies having heteromultimeric and common components
CA2297910A1 (en) 1997-07-25 1999-02-04 Smithkline Beecham Corporation Vitronectin receptor antagonist
EP1007051A4 (en) 1997-08-04 2001-08-29 Smithkline Beecham Corp INTEGRIN RECEPTOR ANTAGONISTS
EP1027337A4 (en) 1997-09-04 2002-04-03 Smithkline Beecham Corp Integrin receptor Antagonist
DZ2609A1 (fr) 1997-09-19 2003-03-01 Smithkline Beecham Corp Composés nouveaux antagonistes des récepteurs de vitronectine et compositions pharmaceutiques les contenant.
CA2303846A1 (en) 1997-09-24 1999-04-01 Smithkline Beecham Corporation Vitronectin receptor antagonist
FR2768734B1 (fr) 1997-09-24 2000-01-28 Roussel Uclaf Nouveaux composes tricycliques, leur procede de preparation et les intermediaires de ce procede, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant
HUP0003931A2 (hu) 1997-09-24 2001-10-28 Smithkline Beecham Corp. Vitronektin receptor antagonisták, valamint a vegyületeket tartalmazó gyógyszerkészítmények
FR2768736B1 (fr) 1997-09-24 2000-05-26 Roussel Uclaf Nouveaux composes tricycliques, leur procede de preparation et les intermediaires de ce procede, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant
DK1040111T3 (da) 1997-12-17 2005-10-10 Merck & Co Inc Integrinreceptorantagonister
JP2002508323A (ja) 1997-12-17 2002-03-19 メルク エンド カムパニー インコーポレーテッド インテグリン受容体拮抗薬
ATE299023T1 (de) 1997-12-17 2005-07-15 Merck & Co Inc Integrinrezeptor antagonisten
GEP20032921B (en) 1997-12-17 2003-03-25 Merck & Co Inc Integrin Receptor Antagonists Pharmaceutical Compositions Containing the Same and Methods for Treatment
US6048861A (en) 1997-12-17 2000-04-11 Merck & Co., Inc. Integrin receptor antagonists
US6017926A (en) 1997-12-17 2000-01-25 Merck & Co., Inc. Integrin receptor antagonists
ATE322508T1 (de) 1998-01-23 2006-04-15 Merck Patent Gmbh Verwendung des antikörpers 271.14d9.f8 (dsm acc2331) um die bindung zwischen alphavbeta6- integrin und fibronectin in vitro zu hemmen
EP1100506A4 (en) 1998-07-29 2002-06-26 Merck & Co Inc INTEGRIN RECEPTOR ANTAGONISTS
JP2002522540A (ja) 1998-08-13 2002-07-23 メルク エンド カムパニー インコーポレーテッド インテグリン受容体拮抗薬
DE19842415A1 (de) 1998-09-16 2000-03-23 Merck Patent Gmbh Pharmazeutische Zubereitung
PL350291A1 (en) 1998-12-23 2002-12-02 Searle & Co Method of using a cyclooxygenase-2 inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
IL146378A0 (en) 1999-06-02 2002-07-25 Merck & Co Inc Alpha v integrin receptor antagonists
EP1328656A4 (en) 2000-09-29 2005-09-14 Univ Johns Hopkins Med METHOD OF PREDICTING CLINICAL REACTION TO CHEMOTHERAPEUTIC TREATMENT WITH ALKYLATING AGENTS
CN101370522A (zh) * 2006-01-18 2009-02-18 默克专利有限公司 使用整联蛋白配体治疗癌症的特别疗法
EP2441464B1 (en) * 2007-01-18 2014-04-09 Merck Patent GmbH Integrin ligands for use in treating colon cancer

Also Published As

Publication number Publication date
WO2010136168A2 (en) 2010-12-02
CL2011002962A1 (es) 2012-06-01
EP2445534A2 (en) 2012-05-02
IL216537A0 (en) 2012-02-29
WO2010136168A8 (en) 2011-09-22
CN102448497A (zh) 2012-05-09
KR20120104491A (ko) 2012-09-21
BRPI1011206A2 (pt) 2016-03-15
NZ597339A (en) 2013-10-25
WO2010136168A3 (en) 2011-07-07
ECSP11011552A (es) 2012-01-31
AU2010252280A1 (en) 2012-01-19
JP2012528079A (ja) 2012-11-12
SG176103A1 (en) 2011-12-29
US20120130146A1 (en) 2012-05-24
CA2763275A1 (en) 2010-12-02
EA201101651A1 (ru) 2012-08-30

Similar Documents

Publication Publication Date Title
MX2011012491A (es) Administracion continua de cilengitida en tratamientos contra el cancer.
Lammers Improving the efficacy of combined modality anticancer therapy using HPMA copolymer-based nanomedicine formulations
WO2007084670A8 (en) Specific therapy using integrin ligands for treating cancer
WO2008087025A3 (en) Specific therapy and medicament using integrin ligands for treating cancer
IN2014DN11099A (es)
PH12017550063A1 (en) Combination therapies for treating cancers
HK1211832A1 (zh) 用於癌症療法的抗高血壓藥物的新穎配方及用法
NZ719049A (en) Cancer treatment with combination of plinabulin and taxane
MX2017014338A (es) Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina.
PH12015502616A1 (en) Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer
SA515370134B1 (ar) تركيبة صيدلانية تحتوي على عامل علاجي قائم على الهيموغلوبين المعدل لعلاج السرطان المستهدف والتصوير التشخيصي
MX2020007130A (es) Métodos para el tratamiento de cánceres metastásicos utilizando receptores señuelo axl.
WO2009140675A3 (en) Combination therapy with pm00104 and another antitumor agent
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
AR066778A1 (es) Terapia combinada para el tratamiento del cancer que comprende vinflunina y trastuzumab
TN2013000333A1 (en) Combinations comprising macitentan for the treatment of glioblastoma multiforme
MX2015015434A (es) Corroles dirigidas para toxicidad tumoral y rm.
WO2013096335A8 (en) ADMINISTRATION OF AN ANTAGONIST OF α5β1 FOR ANTI-ANTIOGENESIS AND CANCER TREATMENT
WO2015038896A3 (en) Wilforlide a for overcoming chemotherapy resistance
MY197664A (en) Immunity enhancing agent for cancer by allergin-1 antagonist
MX2021002884A (es) Terapia de combinacion para el tratamiento de cancer de prostata.
WO2007082742A8 (en) Isolated organ perfusion combination therapy of cancer
WO2010057596A3 (en) New therapy and medicament using integrin ligands for treating cancer
MX2010009697A (es) Tratamientos anticancerigenos mejorados.
WO2008039525A3 (en) Cadherin antagonists in combination with anticancer agents for use in cancer treatment

Legal Events

Date Code Title Description
FA Abandonment or withdrawal